BRCA1 and ovarian carcinoma: In addition, loss of RAD51C promoter methylation has also been reported to confer PARPi resistance (65), with loss of methylation in a single copy being sufficient to cause PARPi resistance (66), as was previously shown in BRCA1-hypermethylated ovarian cancers.